1. Scrip
  2. >>Business
  3. >>Deals

BioNTech Gets In On ADC Action With DualityBio Licensing Deal

 
• By Alaric DeArment

The German biotech is spending some of its pandemic capital on two antibody-drug conjugate candidates from the Chinese firm, including one in Phase II development.

BioNTech and DualityBio signed a licensing deal for two antibody-drug conjugate candidates • Source: Shutterstock

BioNTech SE’s deal to license two antibody-drug conjugates (ADCs) from Duality Biologics further expands the German biotech’s pipeline, which has grown rapidly thanks to its cash windfall from sales of its messenger RNA COVID-19 vaccines. It also illustrates the continuing appeal of ADCs in oncology, especially after partner Pfizer Inc.’s recent megadeal to acquire Seagen Inc. , as a dozen of the drugs have hit the US market since 2017.

The two companies said on 3 April that DualityBio, based in China, had granted BioNTech an exclusive license for two...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

In Brief: BioVersys And Shionogi Align In Non-Tuberculous Mycobacteria R&D

 
• By Joseph Haas

Deal Snapshot: Having recently raised an $89m IPO, BioVersys is partnering on and optioning rights to a preclinical NTM development program with Shionogi.

BerGenBio Plumps For Oncoinvent From Long List Of 50 Suitors

 
• By Kevin Grogan

The merger with a fellow Norwegian biotech comes a few months after its lead asset, bemcentinib, bit the dust.

BlissBio Goes Solo On HER2-Targeting ADC After Eisai Exit

 
• By Dexter Jie Yan

BlissBio is to single-handedly move BB-1701, its eribulin-containing, HER2-targeting antibody-drug conjugate, into a global pivotal Phase II/III program for HER2-expressing, Enhertu-resistant breast cancer.

In Brief: Sanofi Cements Support For Adagene

 
• By Kevin Grogan

Deal Snapshot: The French drugmaker has been shifting its investments away from cancer to focus on immunology and inflammation but it continues to seek out interesting early-stage oncology assets.

More from Business

Protagonist Hopes To Come From Behind In Obesity With Oral Triple Agonist

 
• By Jessica Merrill

The company announced plans to move an oral GLP-1/GIP/GCG receptor agonist peptide into clinical development for obesity in 2026.

In Brief: Sanofi Cements Support For Adagene

 
• By Kevin Grogan

Deal Snapshot: The French drugmaker has been shifting its investments away from cancer to focus on immunology and inflammation but it continues to seek out interesting early-stage oncology assets.

In Vivo CAR-T Interest Grows With AbbVie Acquisition

 
• By Andrew McConaghie

Acquiring Capstan gives AbbVie a stake in two competing in vivo CAR-T delivery platforms, with the field's first readouts expected in 2026.